B2B fieldwork benchmarks: what incidence and cost look like in practice
Incidence assumptions carried over from consumer research are the usual reason a B2B study runs over. Here is what the field data actually shows.
Read more
Industries
Healthcare research carries obligations that most sectors do not: verified professionals, informed patients, adverse event handling and a documentary trail that survives audit. Dnexus Global runs healthcare fieldwork to those standards as a matter of course.
Research solutions
Licence-verified physicians recruited by specialty, practice setting, patient volume and prescribing behaviour, for quantitative trackers and in-depth qualitative work alike. Honorarium handling and transparency reporting are managed as part of the project.
Condition-specific patient populations, including rare disease, reached through advocacy networks and clinical referral. Consent, safeguarding and adverse event reporting protocols are agreed before any outreach starts.
Payers, formulary decision-makers, hospital procurement and health economics stakeholders — audiences small enough that sampling is a sourcing exercise rather than a panel query.
How we work in this sector
Adverse event identification and reporting workflows run alongside data collection, not after it. Interviewers are trained on what constitutes a reportable event, and the escalation path to your pharmacovigilance team is agreed before fieldwork opens. Consent records, screener responses and verification evidence are retained in a form that stands up to audit.
Oncology, cardiology, immunology, neurology, rare disease, primary care and health systems research. Where a therapeutic area needs specialist recruiters we allocate them, because a recruiter who cannot hold a credible conversation about the condition will not reach the clinicians who matter.
Pharmaceutical and device clients operate under codes that constrain how research can be conducted and how respondents can be compensated. We work inside those constraints, document what we did, and flag anything in a brief that would put you outside them.
Featured insights
Benchmarks and analysis drawn from the fieldwork we run.
Incidence assumptions carried over from consumer research are the usual reason a B2B study runs over. Here is what the field data actually shows.
Read moreDifferences between markets in a multi-country study are part finding and part artefact. Separating them is a design problem, not an analysis problem.
Read moreOther sectors
Feasibility, incidence and costs within one working day — including the markets where your target, as written, is not achievable.